USANA Health Sciences (NYSE:USNA) Stock Rating Lowered by Zacks Research

USANA Health Sciences (NYSE:USNA) was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued to investors on Wednesday, Zacks reports.

Other research analysts have also issued reports about the stock. Wall Street Zen lowered shares of USANA Health Sciences from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings restated a “sell (d)” rating on shares of USANA Health Sciences in a research report on Monday, September 21st. Two equities research analysts have rated the stock with a Sell rating. Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

USANA Health Sciences Stock Down 3.3%

Shares of NYSE USNA opened at $13.86 on Wednesday. The firm has a 50-day simple moving average of $14.61 and a 200-day simple moving average of $17.99. The stock has a market capitalization of $256.05 million, a price-to-earnings ratio of -12.05, a price-to-earnings-growth ratio of 2.17 and a beta of 0.66. USANA Health Sciences has a 52 week low of $12.57 and a 52 week high of $23.59.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.22). The business had revenue of $205.89 million during the quarter, compared to analysts’ expectations of $217.42 million. USANA Health Sciences had a positive return on equity of 3.56% and a negative net margin of 2.34%. As a group, equities research analysts expect that USANA Health Sciences will post 0.55 EPS for the current year.

Hedge Funds Weigh In On USANA Health Sciences

A number of institutional investors have recently bought and sold shares of the company. BlackRock Inc. acquired a new position in USANA Health Sciences in the 2nd quarter valued at about $33,182,000. Pzena Investment Management LLC purchased a new stake in shares of USANA Health Sciences in the 2nd quarter valued at approximately $25,739,000. Nantahala Capital Management LLC purchased a new stake in shares of USANA Health Sciences in the 2nd quarter valued at approximately $17,295,080. Algert Global LLC increased its holdings in shares of USANA Health Sciences by 91.8% during the 2nd quarter. Algert Global LLC now owns 131,758 shares of the company’s stock worth $2,813,000 after buying an additional 63,074 shares during the last quarter. Finally, Empowered Funds LLC acquired a new stake in shares of USANA Health Sciences during the 2nd quarter worth approximately $1,500,000. 54.25% of the stock is owned by hedge funds and other institutional investors.

More USANA Health Sciences News

Here are the key news stories impacting USANA Health Sciences this week:

• Positive Sentiment: Sidoti slightly raised its Q4 2026 EPS estimate to $0.12 from $0.11, a modest offset to its broader forecast reductions. USANA analyst estimates
• Negative Sentiment: USANA’s Q3 2026 results missed expectations: the company reported a loss of $0.11 per share versus consensus earnings of $0.11, while revenue of $205.9 million fell short of the $217.4 million estimate. Sales declined 4% year over year. USANA Q3 results and outlook
• Negative Sentiment: The company lowered its FY2026 outlook, now projecting net sales approaching $900 million and adjusted EBITDA of approximately $77 million. The reduced guidance suggests weaker near-term business performance. USANA updates its outlook
• Negative Sentiment: Sidoti lowered its FY2027 EPS forecast to $1.59 from $1.77 and cut estimates for Q1, Q2, and Q3 2027, indicating less confidence in earnings growth beyond 2026. USANA analyst estimates

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and sells nutritional supplements, healthy foods and personal-care products through a direct-selling business model. Its product portfolio includes vitamins and mineral supplements, meal-replacement and snack products, sports nutrition offerings, and skincare products marketed under the USANA and related brands.

Founded in 1992 by microbiologist and immunologist Myron W. Wentz, the company is headquartered in Salt Lake City, Utah. USANA distributes its products through a network of independent associates and preferred customers rather than primarily through traditional retail channels.

The company serves customers in markets across the Americas, Asia-Pacific and Europe, with a significant presence in countries including the United States, Canada, Australia, New Zealand, China, Hong Kong, Japan, South Korea, the Philippines, Singapore, Malaysia and Thailand.